Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease

New investors include Eventide, RTW, Perceptive Advisors, Cormorant Capital, Cowen Healthcare Investments and Point72 Proceeds to accelerate clinical development of PRA023, a potential best in class TL1A antibody for IBD, and expansion of Promtheus' 360... Biopharmaceuticals, Venture Capital, Personnel Prometheus Biosciences, precision medicine, inflammatory bowel disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news